India's Lupin in US Suprax Marketing Deal

The US unit of Indian drugmaker Lupin has agreed a marketing partnership deal with Cornerstone BioPharma Inc to promote its Suprax (cefixime) anti-infective. Company sources hope that the deal will improve penetration of the product in the US oral suspension anti-infective market, which is valued at some US$1.2bn annually. Financial terms of the deal were not disclosed.